Google backs a $60M transition round for FLX’s switch to a CCR4 strategy
FLX Bio isn’t the biotech it started out to be.
Formed as a spinout of Flexus after Bristol-Myers Squibb stepped in to buy the fledgling …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
